相关实验视频
Updated: Feb 23, 2026

06:08
Formulating and Characterizing an Exosome-based Dopamine Carrier System
Published on: April 4, 2022
3.7K
血管痴呆症中的外体介导神经保护:机制,分子途径和治疗前景
Farzaneh Fazli1, Samin Davoody2, Nicole Vissers3
1Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran; Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Molecular and cellular probes
|February 21, 2026
概括
外体细胞通过改善大脑细胞的通信和修复来治疗血管痴呆症 (VaD) 是有前途的. 它们穿越血脑屏障的能力使得它们成为开发新的VaD疗法的关键焦点.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物医学工程 生物医学工程
背景情况:
- 血管痴呆症 (VaD) 是一种常见的神经疾病,其特点是认知能力下降,与海马体损伤和记忆力受损有关.
- 外体,纳米级的细胞外囊泡,对于中枢神经系统内的细胞间通信至关重要.
- 目前的VaD治疗主要是症状性,突出了疾病修饰干预措施的必要性.
研究的目的:
- 审查外体在中枢神经系统功能中的作用.
- 检查基于外体的治疗策略对VaD的最新进展.
- 讨论对外体治疗的临床转化所面临的挑战和未来方向.
主要方法:
- 对外体和VaD的当前研究的文献综述.
- 对外体功能的分析,包括突触可塑性,神经炎症,亡和血管生成.
- 评估基于外体的治疗方法及其穿越血脑屏障的潜力.
主要成果:
- 外体细胞通过运输生物活性分子来促进细胞间的通信.
- 外体通过增强突触可塑性,调节神经炎症,抑制细胞亡和促进血管生成来证明VaD的治疗潜力.
- 外体具有穿越血脑屏障的独特能力,使得有针对性的治疗药物可以被提供.
结论:
- 外体体是血管性痴呆症的有希望的治疗途径,因为它们具有多方面的神经保护作用.
- 进一步的研究和开发对于克服基于外体的VaD疗法的临床转化方面的挑战至关重要.
- 基于外体的干预措施为VaD提供了疾病修饰治疗的潜在途径,超越目前的症状管理.
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
The Blood-brain Barrier
53.8K
Overview
53.8K
Overview of Exosomes
3.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.8K
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K

